Double-Punch combo trial aims to knock out tough lymphoma
NCT ID NCT07326371
Summary
This study is testing whether combining two powerful treatments—CAR-T cell therapy and a drug called glofitamab—is safe and effective for people with high-risk, relapsed, or hard-to-treat large B-cell lymphoma. It will enroll about 24 participants at a single hospital in China. The main goal is to see how many patients achieve a complete disappearance of their cancer after receiving this combination treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.